English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Successful clinical cancer chemoprevention with retinoids was promised by compelling preclinical and early clinical evidence. Indeed, the concept of cancer chemoprevention came largely from studies showing retinoid suppression of epithelial carcinogenesis ([1][1]–[4][2]). Yet, randomized phase III

Retinoid Chemoprevention Trials: Cyclin D1 in the Crosshairs